Regeneron’s antibody treatment has been shown to significantly cut the risk of death among some hospitalized Covid-19 patients
has been shown to significantly cut the risk of death among certain hospitalized Covid-19 patients, raising hopes for a valuable new tool for tackling severe cases.
The results released Wednesday by the U.K. researchers are a boost for a drug class that until now had only been shown to work against milder forms of the disease. Antibody therapies for Covid-19 target the spike protein on the surface of the virus with the aim of preventing it from entering cells.
of dying by 17% in all hospitalized patients. “Now you’re layering the effect of steroids,” said George Yancopoulos, Regeneron’s president and chief scientific officer. “That’s what makes it exciting.”Covid-19 Ranged From Illinois to Massachusetts Before States Reported First Cases
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AstraZeneca’s Covid-19 Antibody Treatment Failed To Prevent Symptoms In Exposed IndividualsThe monoclonal antibody treatment reduced the risk of developing symptomatic Covid-19 by a statistically insignificant 33% among unvaccinated adults.
Read more »
YouTube suspends GOP Sen. Ron Johnson's account, says he violated Covid-19 policyYouTube suspended Sen. Ron Johnson’s account on Friday after the Wisconsin Republican posted his recent remarks about alternative therapies to treat Covid-19.
Read more »
Novavax announces its COVID-19 vaccine is over 90% effective against symptomatic diseaseJUST IN: American biotechnology company Novavax announces that its experimental COVID-19 vaccine is more than 90% effective against symptomatic disease in late-stage clinical trials.
Read more »
Novavax: Large study finds COVID-19 shot about 90% effectiveVaccine maker Novavax said Monday its shot was highly effective against COVID-19 and also protected against variants in a large, late-stage study in the U.S. and Mexico. The vaccine was about 90% effective overall and preliminary data showed it was safe, the company said.
Read more »
Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trialJUST IN: Novavax says its coronavirus vaccine has an overall efficacy of 90.4% and was 'generally well-tolerated' in a Phase 3 trial in the US and Mexico
Read more »